Pharmacy

September 09, 2022

Agenda includes sessions on overall trends in the pharmacy benefit management industry, digital therapeutics and biosimilars.

September 07, 2022

August 22, 2022

The respondents were almost evenly split on whether it was a mistake for the FDA to approve Aduhelm, but a large majority agreed that CMS made the right decision to restrict Medicare coverage to those enrolled in clinical trials.

August 19, 2022

Opinion was split evenly on preexposure prophylaxis as a strategy for preventing HIV infections.

August 18, 2022

Two-thirds of the respondents to our 2022 annual Pharmacy Survey believe that biosimilars will have a significant effect on drugs prices over the next several years.

August 17, 2022

August 16, 2022

Our survey shows some optimism about the course of the COVID-19 pandemic, but concern about Paxlovid rebound. Former President Donald Trump’s job performance on COVID-19 was rated low while the World Health Organization and Pfizer were rated high.

August 05, 2022

An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.

June 24, 2022

Harvard researchers calculated that buying 77 generic drugs at prices being charged by Mark Cuban’s online pharmacy prices would have lowered Medicare spending on those drugs from $9.6 billion to $6 billion.

June 17, 2022

A week after announcing a study of the PBM industry, the Federal Trade Commission announced yesterday that it was stepping up possible enforcement actions targeting the industry's rebate practices. Rebates to exclude lower costs from formularies may constitute commercial bribery under the Robinson-Patman Act, the commission said.